Life Insurance Industry Trends 2026: From Record Sales to a Generational Crossroads

The Big Picture: A Post-Surge Normalization

The U.S. life insurance industry enters 2026 in an unusual position: buoyed by four consecutive years of record-breaking performance but facing unmistakable signals that the growth cycle is cooling. From tracking LIMRA data releases over the past several quarters, the trajectory is clear. In 2024, individual life insurance premium reached an all-time high of $15.9 billion. Through the first nine months of 2025, total new annualized premium surged 12–13% year-over-year to $12.7 billion, driven by double-digit gains in indexed universal life (IUL), variable universal life (VUL), and whole life products.

But the era of double-digit growth appears to be over, at least temporarily. LIMRA projects individual life insurance new annualized premium will grow between 2% and 6% in 2026, which, while still above the historical average of 3.1%, represents a notable deceleration from the exceptional performance of 2025. In a more refined forecast shared by Bryan Hodgens, LIMRA's head of research, the range narrowed to 2–4%, with the acknowledgment that 2025 was "a bit of an outlier."

For actuaries modeling new business volumes and reserve projections, this moderation matters. The question is not whether the industry will grow but rather which product lines, distribution channels, and risk factors will define the 2026 vintage of policies. From what we have observed in the data, the answers point to some significant structural shifts.

Product Mix Shift: IUL and VUL Dominate the Growth Story

Perhaps the most consequential trend for actuaries to monitor is the dramatic reshaping of the individual life product mix. According to Milliman's five-year industry analysis, indexed and variable universal life products expanded to a combined 42% of the individual life market in 2024, up from 30% in 2019. Fixed and guaranteed UL simultaneously contracted from 12% to 6% of the market, a halving that reflects both consumer appetite for accumulation features and the interest rate environment's impact on guaranteed product economics.

The specific product-level data from LIMRA's Q3 2025 results tells the story in sharper detail:

U.S. Individual Life Insurance Sales by Product, First 9 Months 2025 (LIMRA)

Product Line	YTD New Premium	YTD Premium Growth (YoY)	Market Share
Whole Life	$4.6 billion	+6%	36%
Indexed Universal Life (IUL)	$3.2 billion (record)	+19–20%	25%
Term Life	$2.3 billion	+2%	18%
Variable Universal Life (VUL)	$1.9 billion	+30%	15%
Fixed Universal Life	$726 million	−5%	6%

IUL's record-setting trajectory is worth actuarial attention. The $3.2 billion in year-to-date premium through Q3 2025 represented the highest nine-month total in product history, with nine of the top ten IUL writers reporting growth driven by expanded distribution, enhanced product features, and favorable equity markets. LIMRA attributes the strength to premium financing conditions and continued advisor appetite for accumulation-oriented strategies.

However, LIMRA's 2026 outlook suggests IUL and VUL growth will moderate. Hodgens specifically flagged that the outsized gains in these product lines were "sort of maturing," with fewer large-premium policies being written. LOMA's analysis projects IUL premium growth will normalize from the 21–25% surge of 2025, though it will remain positive. VUL faces additional headwinds as equity markets are projected to soften and the pool of candidates who qualify for private placement products narrows.

Whole life's resurgence is equally notable, particularly the surge in policy count, which grew 18% in Q3 2025, the largest quarterly increase since at least 1990. The driver? Final expense insurance. LIMRA's Karen Terry attributed the growth to middle- and lower-income consumer demand for final expense products, a segment that saw 16% premium growth in 2024. Patterns we have seen in recent demographic data suggest this trend has staying power: as the U.S. population ages and final expense remains one of the few insurance products marketed directly to lower-income households, carriers willing to invest in simplified issue distribution should find a receptive market.

Term life remains the workhorse but is growing slowly, just 2% through the first nine months of 2025. As a predominantly middle-market product, term is highly sensitive to unemployment and consumer price sensitivity, and LOMA projects only about 2% annual growth going forward. For actuaries pricing term products, the modest growth trajectory combined with improving mortality data (discussed below) creates an interesting dynamic for competitive positioning.

The 102-Million-Person Coverage Gap: Why This Matters for Actuaries

Behind the industry's sales success lies a persistent and uncomfortable reality: according to the 2024 Insurance Barometer Study from LIMRA and Life Happens, approximately 102 million American adults are either uninsured or underinsured. Only about 51% of Americans report owning at least one life insurance policy, stable in recent years but dramatically lower than the 63% ownership rate recorded in 2011.

The coverage gap breaks down along predictable demographic lines, but the specifics are worth internalizing:

• Gender: Women are 11 percentage points less likely to have coverage than men, the widest gap in the study's 14-year history, despite women's growing economic influence and financial decision-making power.
• Age: Gen Z shows the highest percentage (49%) indicating they need more coverage, while Baby Boomers show the smallest gap at 27%.
• Income: Among earners making $50,000–$149,999, 39% report needing more life insurance, highlighting the middle-market as the most underserved segment proportional to need.
• Cost misconceptions: 72% of survey participants overestimated the cost of a basic term life policy. Only 25% correctly estimated the price of a 20-year, $250,000 level-term policy for a healthy 30-year-old.

Thirty percent of Americans would face significant financial hardship within just one month of the unexpected death of a primary wage earner. For actuaries involved in product development, distribution strategy, or pricing, this gap represents both a moral imperative and a massive commercial opportunity. The carriers that solve the distribution and education puzzle, making accessible, affordable coverage available through digital channels and workplace benefits, will capture disproportionate market share.

The Under-40 Paradox: Capgemini's World Life Insurance Report 2026

The most revelatory research published in recent months comes from the World Life Insurance Report 2026, a joint Capgemini Research Institute and LIMRA study that surveyed 6,176 consumers under age 40 across 18 markets. The findings crystallize a paradox that should concern every life insurance actuary thinking about long-term business sustainability.

The core finding: 68% of adults under 40 recognize life insurance as essential to long-term financial security, yet current product offerings fundamentally misalign with their priorities, hindering adoption.

The reasons are structural, not merely behavioral:

• Delayed life milestones: 63% of under-40 respondents have no immediate marriage plans, and 84% (both single and married) have no immediate plans to have children. These are the traditional trigger events that have historically driven life insurance purchases.
• Demand for "living benefits": Younger consumers want near-term value - wellness rewards, emergency financial support, coverage for fertility treatments - not products designed primarily for a death benefit they perceive as distant.
• Adoption barriers: Life-stage misalignment (32%), high premium costs (28%), and lack of immediate benefits (25%) are the top reasons under-40s cite for not purchasing life insurance.
• Confusing processes: 1 in 4 consumers turn down life insurance specifically because of confusing processes and complex jargon.

At the same time, the report highlights a massive incoming opportunity. As the great wealth transfer accelerates over the next 15–20 years, millennials and Gen Z expect average inheritances of approximately $106,000 per person. Forty percent of under-40 adults rank life insurance and annuities as the third most important destination for inheritance investment, behind stocks and cash savings.

The digital delivery gap is equally stark. According to the report, 59% of under-40s want direct digital engagement, but only 31% of insurers offer platforms to enable it. Even more telling, 77% of consumers expect comprehensive data-driven recommendations, but just 16% of insurers deliver them at scale. Capgemini forecasts global life insurance premiums will grow at only a 0.9% compound average rate through 2040 if the industry fails to adapt.

For actuaries, the implications touch pricing, product design, reserve methodology, and persistency assumptions. Products built around living benefits require fundamentally different lapse and utilization assumptions than traditional death-benefit-only coverage. The industry must reimagine what it is actually selling, and actuaries are central to making that reimagination financially viable.

Accelerated Underwriting Expands to Higher Face Amounts

From tracking industry announcements and regulatory developments over the past year, one of the clearest operational trends is the expansion of accelerated underwriting (AUW) programs to significantly higher face amounts. What was once limited to smaller, simplified-issue policies has evolved dramatically: some carriers now approve face amounts as high as $5 million without requiring traditional medical exams, relying instead on electronic health records, prescription databases, credit proxies, and behavioral data.

The adoption numbers underscore how deeply embedded AI has become in life insurance operations. According to research from LIMRA and UCT, 87% of life insurance carriers are already using AI in one or more operational areas, and 100% are either utilizing large language models or testing them for deployment within the next 12–24 months. A separate NAIC survey found that 58% of life insurers report current or planned AI usage, the lowest among insurance segments surveyed (compared to 92% of health insurers and 88% of auto insurers), but rising rapidly.

The speed improvements are remarkable. According to a 2025 technical analysis cited by BizTech Magazine, AI has reduced the average underwriting decision time from three to five days down to 12.4 minutes for standard policies, while maintaining a 99.3% accuracy rate in risk assessment. For complex policies, AI reduced processing times by 31% and improved risk assessment accuracy by 43%.

However, accelerated underwriting brings its own actuarial challenges. Swiss Re has flagged that industry mortality slippage - the gap between expected and actual mortality in underwritten populations - currently averages around 15%, with individual AUW programs ranging from 5% to over 30%. This means roughly one in six life insurance policies may be fundamentally mispriced. The actuarial profession must grapple with how to validate AUW models, monitor emerging experience, and adjust assumptions as the population of AUW-approved lives grows as a proportion of in-force business.

The NAIC completed its Accelerated Underwriting Educational Report in 2022 and has continued developing regulatory guidance. By late 2025, 23 states and Washington, D.C. had adopted the NAIC's AI Model Bulletin, and a model law on third-party data and model oversight is anticipated in 2026. Actuaries working in product development and compliance should expect increasing scrutiny of AUW model validation, bias testing, and documentation requirements. For more on the regulatory landscape, see our NAIC AI Regulation in Insurance 2026 analysis.

GLP-1 Drugs: A Potential Game-Changer for Mortality Assumptions

No discussion of life insurance trends in 2026 would be complete without addressing the actuarial implications of GLP-1 receptor agonist medications - drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) that have demonstrated significant impacts on obesity, cardiovascular disease, and potentially all-cause mortality.

The data emerging from major reinsurers is striking. A Munich Re study of 41 million insured lives across the United States (2015 through January 2025) found that GLP-1 users demonstrated lower all-cause mortality compared to non-users in both diabetic and non-diabetic populations. Clinical trial data showed semaglutide produced a 20% reduction in major cardiovascular events and a 19% improvement in all-cause mortality. Real-world studies have shown mortality risk reductions of up to 43% among certain patient groups.

Swiss Re's analysis projects that under an optimistic scenario of broad GLP-1 uptake with sustained adherence, these medications could reduce U.S. all-cause mortality by as much as 6.4% by 2045. Given that the U.S. has the developed world's highest adult obesity rate (over 40%), the mortality improvement potential is substantial.

However, actuaries must model the significant uncertainties:

• Adherence rates are poor: Munich Re's data shows that among non-diabetic users, one-year adherence rates fall below 40%, with those aged 30–40 showing fewer than 30% continuing beyond one year. Cost (often $500–$1,000+ per month without insurance) and gastrointestinal side effects (64.4% citing nausea) drive discontinuation.
• Insurance coverage is worsening: Starting January 2026, several major insurers - including BCBS, Cigna, and UnitedHealthcare - restricted coverage of GLP-1 medications for weight management. The number of people with no commercial insurance coverage for Wegovy increased 42% compared to 2025.
• Underwriting challenges are multiplying: Carriers are grappling with how to classify applicants who have lost significant weight on GLP-1 medications. Many underwriters now add approximately half of recent weight loss back into their risk calculations, and standard practice is evolving rapidly.
• Insured population effects may be smaller: RGA's modeling indicates that because insured populations typically have lower average BMI and different cause-of-death distributions than the general population, the mortality improvement for in-force books may be smaller than population-level projections imply.

Conning's 2026 outlook specifically noted that the L&A sector could begin closely monitoring GLP-1 impacts on mortality, morbidity, and longevity trends this year. For reserving actuaries, the key question is whether and when to adjust mortality improvement assumptions. RGA advises that it may be too early to make material adjustments to insured trend assumptions, but the efficacy data increases confidence in future mortality improvements, making current assumptions look increasingly conservative.

The parallel to statins is instructive. Over time, underwriters came to view statin use as proactive health management, with insurers eventually preferring applicants who demonstrated improved health markers through medication. GLP-1s may follow a similar trajectory, but the path there will require years of emerging experience data and careful actuarial judgment.

Estate Tax Reform: The OBBBA Changes the Planning Calculus

The One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025, permanently increased the federal estate and gift tax exemption to $15 million per individual ($30 million for married couples) effective January 1, 2026, with annual inflation indexing going forward. This resolved years of uncertainty created by the TCJA's sunset provision, which would have slashed the exemption to approximately $7 million per person.

For the life insurance industry, the implications are nuanced rather than straightforward. LOMA's analysis noted that the increased exemption reduces uncertainty in estate planning and may dampen survivorship life insurance sales, since fewer estates will face federal tax liability. However, LOMA also observed that clarity often stabilizes demand, as the years of sunset uncertainty had been suppressing estate planning activity and the permanent resolution may actually re-energize the market for high-net-worth planning.

Key considerations for actuaries:

• Survivorship and second-to-die products may face reduced demand for pure estate tax mitigation, though they remain relevant for liquidity planning, equalization of bequests, and charitable giving strategies.
• Irrevocable life insurance trusts (ILITs) remain critical for estates above $15 million, and life insurance death benefits still count toward estate value if the insured owns the policy, creating ongoing need for trust-owned coverage.
• State-level estate taxes in 18 states and jurisdictions remain unaffected by the federal change, maintaining demand for life insurance planning in states like New York (exemption $7.16 million) and others with much lower thresholds.
• Buy-sell agreements: Life insurance remains essential for funding buy-sell agreements in closely held businesses, regardless of estate tax exposure.

The net impact on industry premium volume is likely a modest headwind for the high-net-worth estate planning segment, partially offset by increased planning clarity and continued demand for non-tax-driven uses of permanent life insurance.

Private Equity's Expanding Footprint

The convergence of private capital and life insurance continues to accelerate and reshape the industry's competitive landscape. According to NAIC data, 137 U.S. insurers were identified as private equity-owned at year-end 2024. McKinsey reports that private-capital firms have completed more than $900 billion in transactions acquiring life and annuity liabilities since the global financial crisis, and today account for 35% of new sales in fixed and fixed-indexed annuities, up from just 7% in 2011.

Major recent transactions illustrate the scale and pace:

• Acquarian's $4.1 billion acquisition of Brighthouse Financial (announced November 2025), deepening its presence in the U.S. life and annuity market.
• Nippon Life's acquisition of Resolution Life Group Holdings from Blackstone, representing cross-border expansion into U.S. life liabilities.
• Meiji Yasuda's announced acquisition of Legal & General's U.S. Life Assurance business, another example of Japanese capital entering the U.S. market.

Insurance M&A deal value reached approximately $104 billion in 2025, up from $88 billion in 2024 according to McKinsey, and PwC's 2026 outlook projects activity will remain at similar levels.

For actuaries, the PE influence raises important considerations. PE-owned insurers typically invest three to four times more in private asset classes - including asset-backed securities and real assets - than traditional life insurers, taking on more credit and liquidity risk. About one-third of the industry's $6 trillion of assets are now parked in some form of private credit, according to Moody's Ratings. The NAIC's Macroprudential Working Group has PE-related monitoring as a 2026 priority, and Bermuda has been tightening reinsurance regulations. Actuaries involved in asset adequacy testing, cash flow testing, and risk-based capital assessment must ensure their frameworks adequately capture the risk profile of increasingly complex investment portfolios.

Technology and AI: From Pilot to Production

As we noted in our comprehensive analysis of AI in insurance underwriting, 2026 marks a shift from experimentation to operational deployment across the life insurance value chain. LIMRA's forecast identifies AI as one of the key tailwinds supporting continued industry growth, citing AI-driven improvements in underwriting, service, sales enablement, and cost efficiency.

Several specific developments are worth tracking:

LLM adoption is universal among carriers. LIMRA and UCT research shows 100% of surveyed life insurers are either using large language models in production or testing them for deployment. Applications range from processing Attending Physician Statements and financial records to supporting underwriting teams in flagging inconsistencies and enabling faster decision-making.

Legacy system modernization remains the bottleneck. Equisoft and LIC research found that 38% of carriers cite legacy IT systems lacking automation capabilities as their primary challenge in expediting underwriting decisions, while 45% view self-service tools for brokers and agents as the digital transformation initiative with the most significant impact on underwriting speed.

Regulatory frameworks are crystallizing. By late 2025, 23 states had adopted the NAIC's AI Model Bulletin, and a model law on third-party oversight is anticipated in 2026. Colorado's Artificial Intelligence Act will require insurers to follow governance and testing procedures to prevent unfair discrimination.

The AI in insurance market is growing explosively. According to Fortune Business Insights, the global market was valued at $10.36 billion in 2025 and is projected to grow at a 35.7% CAGR through 2034, with the underwriting segment growing at the fastest rate (41.6% CAGR). The U.S. market alone is estimated at $3.23 billion.

Economic Factors Shaping the 2026 Outlook

The economic backdrop matters enormously for life insurance sales, and the outlook is mixed. From tracking multiple industry forecasts and macroeconomic projections, several factors will influence 2026 outcomes.

Interest rates trending lower. The Fed's continued rate policy shift supports premium financing for IUL products but puts pressure on whole life dividend scales and fixed product economics. LOMA projects lower rates will shift whole life sales toward shorter-pay premiums.

Equity market softness expected. Projections suggest equity markets may decline in 2026 before recovering in 2027, which directly impacts VUL performance and sales. LOMA specifically highlighted the emergence of indexed variable universal life (iVUL) products that could divert some sales from the IUL line, adding another competitive dynamic.

Unemployment rising. Expected to increase through 2027, rising unemployment weighs on middle-market products, particularly term life insurance, which is most sensitive to household budget pressures.

Aging demographics. The U.S. is in "Peak 65," with birth rates declining and traditional life insurance purchase triggers being delayed across generations. LIMRA notes that the over-60 population has become a "saturated market" for life insurance, while younger cohorts are not entering the market at sufficient rates.

Consumer confidence. Inflation has eased but prices remain elevated. LIMRA's research shows consumers gravitate to whole life products during uncertain economic conditions, which helps explain that product's recent resurgence.

Actuarial Implications and What to Watch

For actuaries across all practice areas - from pricing and valuation to enterprise risk management - the 2026 life insurance landscape presents several critical monitoring priorities.

1. Mortality assumption updates. The convergence of improving population mortality (pre-COVID trends resuming), GLP-1 medication impacts, and accelerated underwriting selection effects creates a complex environment for setting mortality assumptions. Conservative assumptions may be leaving money on the table; aggressive assumptions could prove costly if GLP-1 adherence rates do not improve.

2. IUL illustration regulation. The NAIC released an exposure draft regarding potential changes to Actuarial Guideline 49-A, which governs how IUL policies are illustrated. Any changes will take time to implement but could meaningfully affect competitive positioning and sales volumes for the industry's fastest-growing product line.

3. Persistency and lapse assumptions for newer products. As the product mix shifts toward IUL, VUL, and living-benefit-enhanced products, actuaries need emerging experience data on lapse patterns, utilization of accelerated death benefits and riders, and policyholder behavior under different economic scenarios. Historical experience on traditional products may not be representative.

4. Asset-liability matching in a PE-influenced landscape. With PE-owned carriers investing more heavily in private credit and illiquid assets, actuaries performing asset adequacy testing must ensure their models capture liquidity risk, mark-to-market uncertainty, and concentration risk that traditional investment portfolios did not present.

5. Workforce implications. As we detailed in our analysis of the insurance workforce crisis, the talent pipeline for actuaries and data scientists is constrained. Carriers that invest in AI-augmented actuarial workflows - freeing actuaries from routine modeling tasks to focus on judgment-intensive analysis - will have a significant competitive advantage. For aspiring actuaries entering the profession, the 2026 SOA exam pathway redesign is responding to some of these evolving skill demands.